mannitol (Rx)

Brand and Other Names:Osmitrol
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 5%
  • 10%
  • 15%
  • 20%
  • 25%

Elevated Intracranial Pressusre

Indicated for reduction of intracranial pressure associated with cerebral edema and/or brain mass

1.25 g/kg IV infused over 30-60 minutes; may repeat q6-8hr  

Elevated Intraocular Pressure

1.5-2 g/kg IV infused over 30-60 minutes  

When used preoperatively, administer 1-1.5hr before surgery for maximal reduction of IP before operation

Dosing Considerations

During and following drug infusion, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac and pulmonary function; discontinue infusion if renal, cardiac, or pulmonary status worsens or CNS toxicity develops

Dosage Forms & Strengths

injectable solution

  • 5%
  • 10%
  • 15%
  • 20%
  • 25%

Elevated Intracranial Pressure

0.25-1 g/kg IV initially; maintenance dose of 0.25-0.5 g/kg IV q4-6hr  

Elevated Intraocular Pressure

1.5-2 g/kg of a 20% solution (7.5-10 mL/kg) as single dose infused IV over 30-60 minutes  

When used preoperatively, administer 1-1.5 hr before surgery for maximal reduction of IOP before operation

Dosing Considerations

During and following drug infusion, monitor fluid and electrolytes, serum osmolarity, and renal, cardiac and pulmonary function; discontinue infusion if renal, cardiac, or pulmonary status worsens or CNS toxicity develops

Next:

Interactions

Interaction Checker

and mannitol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (1)

              • tobramycin

                mannitol increases levels of tobramycin by unspecified interaction mechanism. Contraindicated.

              Monitor Closely (6)

              • dichlorphenamide

                dichlorphenamide and mannitol both decrease serum potassium. Use Caution/Monitor.

                dichlorphenamide, mannitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

              • lurasidone

                lurasidone increases effects of mannitol by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.

              • nitroglycerin rectal

                nitroglycerin rectal, mannitol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .

              • sodium sulfate/?magnesium sulfate/potassium chloride

                sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of mannitol by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

              • sodium sulfate/potassium sulfate/magnesium sulfate

                sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of mannitol by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

              • tobramycin inhaled

                tobramycin inhaled, mannitol. Either increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent use if possible; mannitol may alter serum/tissue levels of aminoglycosides .

              Minor (6)

              • entecavir

                mannitol, entecavir. Either increases effects of the other by decreasing renal clearance. Minor/Significance Unknown. Coadministration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.

              • magnesium chloride

                mannitol decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown.

              • magnesium citrate

                mannitol decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown.

              • magnesium hydroxide

                mannitol decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.

              • magnesium oxide

                mannitol decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.

              • magnesium sulfate

                mannitol decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Hypersensitivity reactions: Cardiac arrest, anaphylaxis, hypotension, dyspnea, hypertension, pyrexia, chills, sweating, cough, musculoskeletal stiffness, myalgia, urticarial/rash, pruritus, generalized pain, discomfort, nausea, vomiting, and headache

              Renal failure: acute kidney injury, osmotic nephrosis, azotemia, anuria, hematuria, oliguria, polyuria

              CNS toxicity: Headache, coma, seizures, confusion, lethargy; rebound increase in intracranial pressure; dizziness

              Fluid and electrolyte imbalances: Hypovolemia, hypervolemia, peripheral edema, dehydration, hyponatremia, hypernatremia, hyperkalemia, hypokalemia; metabolic acidosis

              Infusion site reactions: Infection, venous thrombosis or phlebitis, inflammation, pain, rash, erythema, pruritus, compartment syndrome and swelling associated with extravasation

              Cardiac and respiratory disorders: Rhinitis, congestive cardiac failure, pulmonary edema, palpitations, hypotension, hypertension, tachycardia, and angina-like chest pains

              Gastrointestinal disorders: Thirst, dry mouth, nausea, vomiting

              Other: Asthenia, malaise, fever, chills, urticaria

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Anuria

              Severe hypovolemia

              Pre-existing severe pulmonary vascular congestion or pulmonary edema

              Active intracranial bleeding, except during craniotomy

              Cautions

              Infusion of hypertonic solutions through a peripheral vein, at a concentration of 10% w/v or greater, may result in peripheral venous irritation, including phlebitis; other severe infusion site reactions, such as compartment syndrome and swelling associated with extravasation, can occur; administer, preferably, into a large central vein

              Do not mix with blood

              Serious hypersensitivity reactions, including anaphylaxis, hypotension and dyspnea resulting in cardiac arrest and death reported; stop infusion immediately if signs or symptoms of suspected hypersensitivity reaction develop

              Renal complications

              • Renal complications, including irreversible renal failure reported in patients receiving mannitol
              • Reversible, oliguric acute kidney injury (AKI) has occurred with normal pretreatment renal function in patient who received large IV mannitol doses
              • Although the osmotic nephrosis associated with mannitol administration is in principle reversible, osmotic nephrosis in general is known to potentially proceed to chronic or even end-stage renal failure
              • Monitor renal function closely during mannitol infusion
              • Patients with pre-existing renal disease, conditions at high risk for renal failure, or those receiving potentially nephrotoxic drugs or other diuretics, are at increased risk of renal failure following administration
              • Avoid coadministration of nephrotoxic drugs or other diuretics, if possible
              • Patients with oliguric AKI who subsequently develop anuria while receiving mannitol are at risk of CHF, pulmonary edema, hypertensive crisis, coma, and death
              • During and following mannitol infusion for reduction in intracranial pressure, clinically monitor and review laboratory tests for changes in fluid and electrolyte status
              • Discontinue if renal function worsens

              Central nervous system toxicity

              • CNS toxicity manifested by, confusion, lethargy, or coma reported in patients, some resulting in death, in particular in presence of impaired renal function, CNS toxicity may result from high serum mannitol concentrations, serum hyperosmolarity resulting in intracellular dehydration within CNS, hyponatremia or other disturbances of electrolyte and acid/base balance secondary to mannitol administration
              • At high concentrations, mannitol may cross blood brain barrier and interfere with ability of brain to maintain pH of cerebrospinal fluid especially in presence of acidosis
              • In patients with preexisting compromise of blood brain barrier, risk of increasing cerebral edema (general and focal) associated with repeated or continued use of product must be individually weighed against expected benefits
              • A rebound increase of intracranial pressure may occur several hours after infusion; patients with a compromised blood brain barrier are at increased risk
              • Concomitant administration of neurotoxic drugs (eg, aminoglycosides) may potentiate neurotoxicity; avoid concomitant use of neurotoxic drugs, if possible

              Fluid electrolyte imbalance

              • Depending on dosage and duration, administration may result in hypervolemia leading to or exacerbating existing congestive heart failure
              • Accumulation of mannitol due to insufficient renal excretion increases risk of hypervolemia; mannitol-induced osmotic diuresis may cause or worsen dehydration/hypovolemia and hemoconcentration; therapy may also cause hyperosmolarity
              • Depending on dosage and duration of administration, electrolyte and acid/base imbalances may also result from transcellular shifts in water and electrolytes, osmotic diuresis and/or other mechanisms; such imbalances may be severe and potentially fatal
              • Metabolic acidosis/alkalosis
                • Pediatric patients <2 years, particularly preterm and term neonates, may be at higher risk for fluid and electrolyte abnormalities following administration due to decreased glomerular filtration rate and limited ability to concentrate urine
                • During and following infusion for reduction in intracranial pressure, monitor fluid and electrolyte status and discontinue therapy if imbalances occur
              • Imbalances resulting from therapy
                • Hypernatremia, dehydration and hemoconcentration
                • Hyponatremia, which can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death; acute symptomatic hyponatremic encephalopathy is considered a medical emergency
                • Hypo/hyperkalemia; the development of electrolyte imbalances (eg, hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents)
              • During and following infusion for reduction in intracranial pressure, monitor:
                • Serum osmolarity, serum electrolytes (including sodium, potassium, calcium and phosphate) and acid base balance
                • The osmol gap
                • Signs of hypo- or hypervolemia, including urine output
                • Renal, cardiac and pulmonary function
                • Intracranial pressure
                • Discontinue therapy if renal, cardiac, or pulmonary status worsens or CNS toxicity develops

              Drug interaction overview

              • Nephrotoxic drugs
                • Coadministration of nephrotoxic drugs increases renal failure
                • If possible, avoid use with nephrotoxic drugs
              • Diuretics
                • Coadministration of other diuretics may potentiate renal toxicity
                • If possible, avoid use of other diuretics
              • Neurotoxic drugs
                • Coadministration of systemic neurotoxic drugs may potentiate CNS toxicity of mannitol
                • If possible, avoid use of neurotoxic drugs
              • Drugs affected by electrolyte imbalances
                • Development of electrolyte imbalances (eg, hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (eg, digoxin, drugs that prolong the QT interval, neuromuscular blocking agents)
                • Monitor serum electrolytes during and following mannitol infusion; discontinue if cardiac status worsens
              • Renally eliminated drugs
                • May increase elimination and decrease effectiveness of drugs that undergo significant renal elimination
                • Coadministration with lithium may initially increase lithium elimination, but may also increase risk of lithium toxicity if patients develop hypovolemia or renal impairment
                • Consider holding lithium doses during treatment with mannitol
                • If unable to avoid coadministration, frequently monitor serum lithium concentrations for signs of lithium toxicity
              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

              Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus

              Mannitol is present in amniotic fluid when administered to pregnant women during the third trimester of pregnancy

              Animal data

              • No adverse developmental effects from mannitol reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of drug

              Lactation

              There are no data on presence of mannitol in either human or animal milk, effects on breastfed infant, or on milk production

              Consider developmental and health benefits of breastfeeding along with mother’s clinical need for drug and any potential adverse effects on breastfed infant from drug or from underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Osmotic diuretic

              When administered IV, exerts its osmotic effect as a solute of relatively small molecular size being largely confined to the extracellular space

              Mannitol hinders tubular reabsorption of water and enhances excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate

              This increase in extracellular osmolarity will induce the movement of intracellular water to the extracellular and vascular space

              Onset of Action

              Diuresis: 1-3 hr after IV administration of mannitol. Lowering of

              IOP reduction: 30-60 min

              ICP reduction: 15 min

              Duration

              IOP reduction: 4-6 hr

              ICP reduction: 3-8 hr

              Other Information

              Metabolism: liver (very slight)

              Metabolites: glycogen

              Half-life: 100 min

              Excretion: urine (80%)

              Previous
              Next:

              Administration

              IV Incompatibilities:

              Additive: etoposide w/ cisplatin & KCl(?), imipenem-cilastatin (may be used for shorter periods), meropenem (may be used for shorter periods)

              Y-site: cefepime, doxorubicin liposomal, filgrastim

              IV Compatibilities

              Additive (partial list): cefoxitin, cimetidine, furosemide. metoclopramide, ondansetron

              Y-site: allopurinol, cisatracurium, etoposide phosphate, linezolid, ondansetron, propofol, vinorelbine

              IV Preparation

              Infusion only

              Use administration set with filter for infusion of injections containing 20% or more, since crystals may be present

              For transurethral prostatic resection, mannitol irrigation solns are instilled into bladder via indwelling urethral catheter

              IV Administration

              Administer over 30-60 minutes

              Administer IV using sterile, filter-type administration set to ensure against infusion of mannitol crystals

              When administered peripherally, infuse slowly through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation; carefully avoid infiltration

              Do not admix with other drugs

              Storage

              Store at room temperature (25ºC)

              Avoid excessive heat

              Protect from freezing

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.